Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-03-20

FDA Approved: ZEMBRACE SYMTOUCH — Supplemental Application (Upsher-Smith laboratories, LLC)

View source ↗

Summary

FDA supplemental approval for ZEMBRACE SYMTOUCH (sumatriptan succinate) submitted by Upsher-Smith Laboratories, LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ZEMBRACE SYMTOUCH (Sumatriptan succinate)

Snippet

SUPPL AP for ZEMBRACE SYMTOUCH (SUMATRIPTAN SUCCINATE)